Category: New Diagnostics

What You Need to Know About Liquid Biopsies

by Janet Freeman-Daily, Founder of ROS1ders and lung cancer patient/activist, and Lecia V. Sequist, MD, MPH, The Landry Family Associate Professor of Medicine, Harvard Medical School The term “liquid biopsy” is appearing with increasing frequency in the news and lung cancer community discussions. Hundreds of presentations about liquid biopsies were offered this spring at major… Read More

Posted by ALCF Staff on August 15th, 2018

Liquid Biopsy Study Opens for Enrollment

More treatment or just surgery? This a question many physicians face when determining treatment for lung cancer patients. A new clinical study launched by the Addario Lung Cancer Medical Institute (ALCMI), Drs. Ramaswamy Govindan and Daniel Morgensztern, and Inivata hopes to help answer that question in patients with early non-small cell lung cancer (NSCLC). The… Read More

Posted by ALCF Staff on July 18th, 2018

ATS Conference May 2018

At the ATS (American Thoracic Society) was held in San Diego the end of May. While referrals to Low Dose CT (LDCT) screening still remains very low, much discussion occurred around screening and are those who are appropriate being referred. Topics ranged from should physicians and patients adhere to the National Lung Screening Trial (NLST)… Read More

Posted by ALCF Staff on June 29th, 2018

With healthcare reform, Congress can’t forget what works

Laurie Fenton Ambrose and Bonnie J. Addario wrote and Op Ed for “The Hill” about views on healthcare reform. The article states that “healthcare cannot break down into partisan politics…It impacts everyone regardless of politics.” They stress the importance of coverage for people with pre-existing conditions, early detection and access to new medications. Click here… Read More

Posted by ALCF Staff on September 22nd, 2017

Patient Advocacy Strategies Evolve as Genomic Advances Change Understanding of Cancer

The ROS1ders, are throwing their energy behind creating preclinical mouse models and cells lines that will inform drug development efforts and improve understanding… Read More

Posted by ALCF Staff on September 8th, 2017

ALCMI, Champions Oncology, and ROS1ders to Launch Clinical Study

The Addario Lung Cancer Medical Institute (ALCMI), and Champions Oncology (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announce a research collaboration and initiation of the ALCMI-006 study, which was developed and will be conducted by ALCMI and… Read More

Posted by ALCF Staff on August 15th, 2017

Lung Cancer Early Detection Challenge: Concept to Clinic

Looking for data scientists, software engineers, designers and researchers to build an open source software application that puts advances from machine learning into the hands of practicing clinicians. In addition to creating cutting-edge clinical software that helps detect lung cancer early, top contributors are eligible for a share of $100,000 in prize money. Click here… Read More

Posted by ALCF Staff on August 10th, 2017

Lung Cancer Updates from 2017 ASCO Annual Meeting

Each year in early June the American Society for Clinical Oncology holds its Annual Meeting (called simply “ASCO”) in Chicago. The theme for the 2017 meeting was “Making a Difference in Cancer Care WITH YOU.” Over 39,000 cancer researchers, clinicians, patient advocates, and industry representatives from around the world gathered to discuss the latest scientific… Read More

Posted by Janet Freeman-Daily on July 26th, 2017

How Corporations Really Know What’s Good for the Patient

Richard Goodfellow of CEO of biotech Scancell Talks about how patient advocacy groups are central to understanding patient needs. He emphasizes that working with advocacy groups are an innovative and productive way of ensuring patients are at the forefront of everything they do. Click here to read the full commentary

Posted by Richard Goodfellow on July 26th, 2017

Read Bonnie’s blog post about the excitement in Lung Research from ASCO

This year at ASCO, lung cancer was all the buzz. Lung cancer is quickly becoming the lead in the discovery of cancer mutations and other drivers relative to advancing therapies and survival. There are now many possibilities in the future of all cancers beginning with chronic management and onto future cures. Read Bonnie’s blog about… Read More

Posted by ALCF Staff on June 20th, 2017